Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
16
PRTA Quote, Financials, Valuation and Earnings
Last price:
$15.41
Seasonality move
:
10.81%
Day range:
$14.89 - $15.50
52-week range:
$11.70 - $41.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.21x
P/B ratio:
1.54x
Volume:
477.6K
Avg. volume:
637.3K
1-year change:
-60.96%
Market cap:
$824.9M
Revenue:
$91.4M
EPS (TTM):
-$2.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRTA
Prothena Corp PLC
|
$600K | -$1.18 | 2542.37% | -20.98% | $49.75 |
|
AMRN
Amarin Corp PLC
|
$44.5M | -$0.06 | -49.46% | -50% | -- |
|
GHRS
GH Research PLC
|
-- | -$0.25 | -- | -7.14% | -- |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$0.21 | -- | -49.47% | -- |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$1B | $5.50 | 4.77% | 311.88% | $181.05 |
|
MURA
Mural Oncology PLC
|
-- | -$1.96 | -- | -44.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRTA
Prothena Corp PLC
|
$15.33 | $49.75 | $824.9M | -- | $0.00 | 0% | 6.21x |
|
AMRN
Amarin Corp PLC
|
$0.44 | -- | $182.5M | -- | $0.00 | 0% | 0.76x |
|
GHRS
GH Research PLC
|
$7.00 | -- | $364.2M | -- | $0.00 | 0% | -- |
|
ITRM
Iterum Therapeutics PLC
|
$1.78 | -- | $29.5M | -- | $0.00 | 0% | 33.98x |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$124.25 | $181.05 | $7.5B | 17.50x | $0.00 | 0% | 2.06x |
|
MURA
Mural Oncology PLC
|
$3.29 | -- | $56.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRTA
Prothena Corp PLC
|
-- | 1.357 | -- | 11.19x |
|
AMRN
Amarin Corp PLC
|
-- | -1.163 | -- | 2.08x |
|
GHRS
GH Research PLC
|
-- | 0.280 | -- | -- |
|
ITRM
Iterum Therapeutics PLC
|
-- | 1.002 | -- | -- |
|
JAZZ
Jazz Pharmaceuticals PLC
|
59.44% | 0.892 | 90.76% | 3.24x |
|
MURA
Mural Oncology PLC
|
-- | 3.646 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRTA
Prothena Corp PLC
|
-- | -$66.5M | -23.56% | -23.56% | -6857.01% | -$45.2M |
|
AMRN
Amarin Corp PLC
|
$16.3M | -$25.2M | -7.2% | -7.2% | -59.5% | -$2.4M |
|
GHRS
GH Research PLC
|
-- | -$12.6M | -- | -- | -- | -$12.3M |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$6.2M | -- | -- | -- | -$13.1M |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$943.4M | $260.2M | 4.84% | 12.28% | 24.6% | $388M |
|
MURA
Mural Oncology PLC
|
-- | -$34.1M | -- | -- | -- | -$30.1M |
Prothena Corp PLC vs. Competitors
-
Which has Higher Returns PRTA or AMRN?
Amarin Corp PLC has a net margin of -6082.58% compared to Prothena Corp PLC's net margin of -59.42%. Prothena Corp PLC's return on equity of -23.56% beat Amarin Corp PLC's return on equity of -7.2%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp PLC-- -$1.10 $534.4M AMRNAmarin Corp PLC38.48% -$0.06 $531.4M -
What do Analysts Say About PRTA or AMRN?
Prothena Corp PLC has a consensus price target of $49.75, signalling upside risk potential of 224.53%. On the other hand Amarin Corp PLC has an analysts' consensus of -- which suggests that it could grow by 125.43%. Given that Prothena Corp PLC has higher upside potential than Amarin Corp PLC, analysts believe Prothena Corp PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp PLC5 2 0 AMRNAmarin Corp PLC0 2 0 -
Is PRTA or AMRN More Risky?
Prothena Corp PLC has a beta of 0.086, which suggesting that the stock is 91.418% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 1.831, suggesting its more volatile than the S&P 500 by 83.086%.
-
Which is a Better Dividend Stock PRTA or AMRN?
Prothena Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or AMRN?
Prothena Corp PLC quarterly revenues are $970K, which are smaller than Amarin Corp PLC quarterly revenues of $42.3M. Prothena Corp PLC's net income of -$59M is lower than Amarin Corp PLC's net income of -$25.1M. Notably, Prothena Corp PLC's price-to-earnings ratio is -- while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp PLC is 6.21x versus 0.76x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp PLC6.21x -- $970K -$59M AMRNAmarin Corp PLC0.76x -- $42.3M -$25.1M
-
Which has Higher Returns PRTA or GHRS?
GH Research PLC has a net margin of -6082.58% compared to Prothena Corp PLC's net margin of --. Prothena Corp PLC's return on equity of -23.56% beat GH Research PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp PLC-- -$1.10 $534.4M GHRSGH Research PLC-- -$0.23 -- -
What do Analysts Say About PRTA or GHRS?
Prothena Corp PLC has a consensus price target of $49.75, signalling upside risk potential of 224.53%. On the other hand GH Research PLC has an analysts' consensus of -- which suggests that it could grow by 346.43%. Given that GH Research PLC has higher upside potential than Prothena Corp PLC, analysts believe GH Research PLC is more attractive than Prothena Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp PLC5 2 0 GHRSGH Research PLC0 0 0 -
Is PRTA or GHRS More Risky?
Prothena Corp PLC has a beta of 0.086, which suggesting that the stock is 91.418% less volatile than S&P 500. In comparison GH Research PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTA or GHRS?
Prothena Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp PLC pays -- of its earnings as a dividend. GH Research PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or GHRS?
Prothena Corp PLC quarterly revenues are $970K, which are larger than GH Research PLC quarterly revenues of --. Prothena Corp PLC's net income of -$59M is lower than GH Research PLC's net income of -$12.1M. Notably, Prothena Corp PLC's price-to-earnings ratio is -- while GH Research PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp PLC is 6.21x versus -- for GH Research PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp PLC6.21x -- $970K -$59M GHRSGH Research PLC-- -- -- -$12.1M
-
Which has Higher Returns PRTA or ITRM?
Iterum Therapeutics PLC has a net margin of -6082.58% compared to Prothena Corp PLC's net margin of --. Prothena Corp PLC's return on equity of -23.56% beat Iterum Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp PLC-- -$1.10 $534.4M ITRMIterum Therapeutics PLC-- -$0.46 -- -
What do Analysts Say About PRTA or ITRM?
Prothena Corp PLC has a consensus price target of $49.75, signalling upside risk potential of 224.53%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 321.35%. Given that Iterum Therapeutics PLC has higher upside potential than Prothena Corp PLC, analysts believe Iterum Therapeutics PLC is more attractive than Prothena Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp PLC5 2 0 ITRMIterum Therapeutics PLC0 0 0 -
Is PRTA or ITRM More Risky?
Prothena Corp PLC has a beta of 0.086, which suggesting that the stock is 91.418% less volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.404, suggesting its more volatile than the S&P 500 by 140.42%.
-
Which is a Better Dividend Stock PRTA or ITRM?
Prothena Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp PLC pays -- of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or ITRM?
Prothena Corp PLC quarterly revenues are $970K, which are larger than Iterum Therapeutics PLC quarterly revenues of --. Prothena Corp PLC's net income of -$59M is lower than Iterum Therapeutics PLC's net income of -$7.1M. Notably, Prothena Corp PLC's price-to-earnings ratio is -- while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp PLC is 6.21x versus 33.98x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp PLC6.21x -- $970K -$59M ITRMIterum Therapeutics PLC33.98x -- -- -$7.1M
-
Which has Higher Returns PRTA or JAZZ?
Jazz Pharmaceuticals PLC has a net margin of -6082.58% compared to Prothena Corp PLC's net margin of 20.39%. Prothena Corp PLC's return on equity of -23.56% beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp PLC-- -$1.10 $534.4M JAZZJazz Pharmaceuticals PLC89.42% $3.42 $10.3B -
What do Analysts Say About PRTA or JAZZ?
Prothena Corp PLC has a consensus price target of $49.75, signalling upside risk potential of 224.53%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 45.72%. Given that Prothena Corp PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Prothena Corp PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp PLC5 2 0 JAZZJazz Pharmaceuticals PLC8 3 0 -
Is PRTA or JAZZ More Risky?
Prothena Corp PLC has a beta of 0.086, which suggesting that the stock is 91.418% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.
-
Which is a Better Dividend Stock PRTA or JAZZ?
Prothena Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or JAZZ?
Prothena Corp PLC quarterly revenues are $970K, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Prothena Corp PLC's net income of -$59M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, Prothena Corp PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp PLC is 6.21x versus 2.06x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp PLC6.21x -- $970K -$59M JAZZJazz Pharmaceuticals PLC2.06x 17.50x $1.1B $215.1M
-
Which has Higher Returns PRTA or MURA?
Mural Oncology PLC has a net margin of -6082.58% compared to Prothena Corp PLC's net margin of --. Prothena Corp PLC's return on equity of -23.56% beat Mural Oncology PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRTAProthena Corp PLC-- -$1.10 $534.4M MURAMural Oncology PLC-- -$1.87 -- -
What do Analysts Say About PRTA or MURA?
Prothena Corp PLC has a consensus price target of $49.75, signalling upside risk potential of 224.53%. On the other hand Mural Oncology PLC has an analysts' consensus of -- which suggests that it could grow by 396.45%. Given that Mural Oncology PLC has higher upside potential than Prothena Corp PLC, analysts believe Mural Oncology PLC is more attractive than Prothena Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings PRTAProthena Corp PLC5 2 0 MURAMural Oncology PLC0 0 0 -
Is PRTA or MURA More Risky?
Prothena Corp PLC has a beta of 0.086, which suggesting that the stock is 91.418% less volatile than S&P 500. In comparison Mural Oncology PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRTA or MURA?
Prothena Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mural Oncology PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp PLC pays -- of its earnings as a dividend. Mural Oncology PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRTA or MURA?
Prothena Corp PLC quarterly revenues are $970K, which are larger than Mural Oncology PLC quarterly revenues of --. Prothena Corp PLC's net income of -$59M is lower than Mural Oncology PLC's net income of -$31.8M. Notably, Prothena Corp PLC's price-to-earnings ratio is -- while Mural Oncology PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp PLC is 6.21x versus -- for Mural Oncology PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRTAProthena Corp PLC6.21x -- $970K -$59M MURAMural Oncology PLC-- -- -- -$31.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
